HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth

HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, announced Su-jin Park has been appointed as new Co-Chief Executive Officer. Sean Jeong, who has served as a Co-CEO of HanAll Biopharma since March 2021, will continue to lead HanAll’s R&D vision and strategy alongside Mr. Park, who will focus on the business strategy and daily operations of HanAll’s pharmaceutical business, which generated over 100 billion won in revenue in 2022. Both CEOs will collaborate in building the organization and business development to drive HanAll’s next phase of growth in both domestic and global markets.

Mr. Park is an experienced executive with a proven track record of driving growth and delivering results in pharmaceutical sales and marketing for more than 20 years. Most recently he tenured as head of the prescription drug (ETC) marketing and sales division in Daewoong Pharmaceutical, where he provided strategic vision and oversight to drive sales for key products, bringing a record-high ETC sales in company’s history in 2022 with a successful launching of Fexuclue, a medication for gastroesophageal reflux disease.

As a new Co-CEO, Mr. Park will bring his extensive experience and know-how to strengthen HanAll’s domestic drug production and sales.

“I am thrilled to join a team of experts who are globally recognized for their innovation to advance the development and delivery of life-saving medicines. I will work to strengthen our sales strategy of existing pharmaceutical products while expanding our sales network to deliver new products to the patients in need of effective treatment,” said Su-jin Park, Co-CEO of HanAll Biopharma.

About HanAll Biopharma

HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company founded in 1973, with the mission of making meaningful contributions to patients’ lives by introducing innovative, impactful therapies to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for more than 49 years.

HanAll has expanded its focus to ophthalmology, immunology, oncology and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of rare autoimmune disorders including myasthenia gravis, thyroid eye disease, warm autoimmune hymolytic anemia, neuromyelitis optica, and immune thrombocytopenia. Another main asset, HL036 (INN: tanfanercept), an anti-TNF alpha biologic, is being evaluated in Phase 3 clinical trials in the US and China for the treatment of dry eye disease.


Written by Shantel

Jun & Lina Liu Foundation, Established by ATIF CEO Mr. Liu Jun, Officially Launches

Rania Llewellyn, President and CEO of Laurentian Bank to speak at the 21st Annual National Bank Financial Services Conference/